Consolidated sales of global products [IFRS]

(billion yen)

 

FY2016 FY2017
XTANDI 252.1 294.3
 
 
 
 
 
 
US 131.7 144.4
Ex-US 120.4 149.9
 
 
 
 
Japan 23.4 26.1
Americas(Ex-US) 7.7 11.3
EMEA* 85.3 106.7
Asia and Oceania 4 5.8
Vesicare 116.1 102.3
 
 
 
 
Japan 25.6 23.9
Americas 53.1 41.3
EMEA* 32 31.7
Asia and Oceania 5 5
Betanis / Myrbetriq / BETMIGA 98.8 125.7
 
 
 
 
Japan 25.9 29.5
Americas 55.3 72.8
EMEA* 14.1 18.3
Asia and Oceania 3.5 5.2
Prograf 186.2 198.5
 
 
 
 
 
Japan 48.8 48.3
Americas 27.3 25.7
EMEA* 70.1 78.7
Asia and Oceania 37.3 42.5
Exports to third parties 2.6 3.3
Harnal 47.7 49.6
Funguard/Mycamine 40.3 41

*Europe, the Middle East and Africa 

Consolidated Sales of Other Products [IFRS]

Rx Sales in Japan

(billion yen)

 

FY2016 FY2017
Micardis
Micombi
Micamlo
93.2 46.3
Celecox 47.6 48.3
Symbicort 39.3 39.5
Lipitor 23.2 19.6
Myslee 14.7 13.3
Bonoteo 13.8 13.3
Geninax 10.1 9.2
Suglat 9.5 11.6

RX Sales in Americas and Europe

(billion yen)

 

FY2016 FY2017
Scan*
(Americas)
  71.5 73.6
Tarceva US 25.8 21.5
Ex-US 9.4 8.2

* Adenoscan + Lexiscan

Note:

The data used within this site is compiled from the earnings announcements. Frequency of updates may vary due to changes in earnings report format. For more detailed earnings information, please see the earnings releases. This site will not be immediately updated if correction of earnings data and others are announced. In the preparation of the various data shown within this site, we make every effort to ensure its accuracy. But despite our best efforts, the possibility for inaccuracy in the data due to reasons beyond our control exists. The data contained within this page uses service provided by Nomura Investor Relations Co., Ltd.

Powered by